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Abstract
Clinical trials in the medical domain are con-
strained by budgets. The number of patients
that can be recruited is therefore limited.
When a patient population is heterogeneous,
this creates difficulties in learning subgroup
specific responses to a particular drug and es-
pecially for a variety of dosages. In addition,
patient recruitment can be difficult by the
fact that clinical trials do not aim to provide
a benefit to any given patient in the trial. In
this paper, we propose C3T-Budget, a con-
textual constrained clinical trial algorithm for
dose-finding under both budget and safety
constraints. The algorithm aims to maximize
drug efficacy within the clinical trial while also
learning about the drug being tested. C3T-
Budget recruits patients with consideration
of the remaining budget, the remaining time,
and the characteristics of each group, such
as the population distribution, estimated ex-
pected efficacy, and estimation credibility. In
addition, the algorithm aims to avoid unsafe
dosages. These characteristics are further il-
lustrated in a simulated clinical trial study,
which corroborates the theoretical analysis
and demonstrates an efficient budget usage as
well as a balanced learning-treatment trade-
off.
1 INTRODUCTION
Traditionally, dose-finding studies are early stage clini-
cal trials used to evaluate the safety of a new treatment,
and are often referred to as Phase I clinical trials. Thus,
traditional dose-finding methods aim to find the most
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appropriate dose for use in further phases of clinical
trials by considering only toxicity of the treatment
(Storer, 1989; O’Quigley et al., 1990). Recently, how-
ever, both toxicity and efficacy have been considered
in dose-finding methods to accelerate the development
process of new treatments and to reduce costs (Zang
et al., 2014). As the efficacy is considered in dose-
finding, the dose-finding methods should be designed
for both clinical research (i.e., to find the appropriate
dose) and clinical practice (i.e., to benefit the patients
participating) (Berry et al., 2004). This gives rise to an
inevitable trade-off between information gathering and
treatment effectiveness, which makes the dose-finding
problem more complex.
Heterogeneous groups of patients also make the dose-
finding problem more complex (Wages et al., 2015). In
many cases, the efficacy and toxicity of a dose will vary
between groups as shown in Table 1. Thus, with the
heterogeneous groups, the goal of dose-finding clinical
trials is to find the most appropriate dose for each
group. On the other hand, the presence of heteroge-
neous responses can also be a blessing – a drug need
only be effective for a single subgroup for it to be ap-
proved. Furthermore, in general, different groups will
be of different sizes (i.e. a different number of people
belong to each group on a population level), which may
result in inaccurate dose-finding for under-represented
groups (Hussain-Gambles et al., 2004). To avoid this,
an algorithm for dose-finding should account for differ-
ing group sizes (which manifest themselves in terms of
patient enrolment/arrival rates).
In clinical trials, there are several ethical constraints in-
volved with treating human subjects (O’Quigley et al.,
1990) such as a limited number of patients and a careful
consideration for the safety of the patients. These con-
straints highly motivate a clinical trial that effectively
utilizes the limited budget for successfully balancing
the aforementioned trade-off while avoiding unsafe
doses. It is worth noting that such a clinical trial might
be more ethical than the traditional methods since it
more effectively uses the budget and exposes fewer par-
ticipants to unsafe doses (Park et al., 2018; Pallmann
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Table 1: Examples of Studies with Heterogeneous Groups in the Literature
Study Treatment Groups Results
(Polyzos, 2008) Sunitinib Type of cancer
37% RR, 48% SD for renal cell carcinoma,
8% RR, 70% SD for gastrointestinal stromal tumors,
9% RR, 19% SD for lung cancer
(RR: response rate, SD: stable disease)
(Kim et al., 2009) Irinotecan
3 Groups according to
genetic characteristics
350 mg/m2 for group 0 and 1
200 mg/m2 for group 2
(Dasari et al., 2013)
Sorafenib 400 mg bid
with vorinostat 300 mg daily
days 1–14 of a 21-day cycle
Type of cancer
Treatment is not tolerable in renal cell carcinoma
and non-small cell lung cancer patients
while tolerable in other cancer types
(Moss et al., 2015) Ivacaftor Adult and children
Treatment significantly improves lung function
only in adult patients
et al., 2018). In particular, with a joint consideration
of heterogeneous groups and limited budget, the rela-
tionship between clinical research and clinical practice
should be carefully studied. From the point of view of
research, a successful clinical trial with a given limited
budget should concentrate on the groups for which the
estimate of the optimal dose is poor. However, a new
treatment may not be effective for all groups as shown
in Table 1. Thus, from the point of view of practice,
precious budget is being wasted if the trial concentrates
on improving estimates for groups for which the new
treatment is ineffective. Moreover, the differing pop-
ulations of each group should also be considered while
balancing the trade-off, since what can be achieved,
in terms of both research and practice, depends on the
population (Hussain-Gambles et al., 2004).
In this paper, we study a contextual constrained clinical
trial (C3T) problem for dose-finding with both budget
and safety constraints. The goal is to effectively bal-
ance the aforementioned trade-off while avoiding unsafe
doses. In the C3T problem, patients arrive sequentially
(with arrival rates for different groups assumed to be
different), and an agent that administrates the clini-
cal trial determines how a new patient will be treated.
In other words, in the C3T problem, the agent’s first
decision is whether or not the patient is treated (i.e.
accepted into the trial), and if so, the agent should then
determine the dose that will be allocated to the patient.
To answer these two questions, we propose a novel con-
textual multi-armed bandit (MAB) algorithm for C3Ts
with budget constraint called C3T-Budget. In the al-
gorithm, different patient groups are modeled as the
context. In each round, to maximize the effectiveness
of clinical practice, the dose for each group is chosen
to maximize the expected efficacy while satisfying the
safety constraint based on information learned from
previously treated patients. Then, given the chosen
dose, the algorithm determines whether the patient is
treated or not with the aim of maximizing the infor-
mation from clinical research. Specifically, we provide
a linear programming (LP) approximation to the C3T
problem based on the optimal dose, remaining budget,
remaining time, and population of the groups. With the
LP approximation, we can determine whether to treat
a patient or not by maximizing the accuracy improve-
ment of the efficacy estimation, for which a Bayesian
approach is adopted. C3T-Budget can, therefore, sys-
tematically balance the trade-off between treatment
and learning by recruiting patients from appropriate
subgroups. However, when the budget is very limited, it
is hard to balance the trade-off for all subgroups. In this
case, clinical trials should focus on subgroups with high
efficacies since an attempt to focus on all subgroups may
lead to a completely failed trial. To address this, we
propose a modified version of C3T-Budget called C3T-
Budget-E, which concentrates on the subgroups with
estimated high efficacies. Through numerical results,
we show that our algorithms outperform state of the art
in terms of efficacy, safety, and recommendation errors.
1.1 Related Works
MAB models are particularly appropriate for clinical
trials since the trade-off between clinical research and
clinical practice can be seen as the well-known tradeoff
between exploration and exploitation in the context of
MAB, which has been very well-studied. Under this
pretext, the application of novel MAB models tailored
to clinical trials has been widely studied. In Villar
et al. (2015), a patient allocation strategy for clinical
trials is proposed based on the Gittins index. Villar
and Rosenberger (2018) extend the strategy as the
modified forward looking Gittins index to utilize the
covariate information. In Aboutalebi et al. (2019), a
regret model that considers the safety of dosages is
proposed. Based on the regret model, a dose-finding
algorithm is developed, and the regret model helps
the algorithm avoid unsafe dosages when finding the
optimal dosage. In Aziz et al. (2019), a Thompson
sampling-based Phase I clinical trial algorithm is pro-
posed. In the algorithm, both efficacy and toxicity are
considered when finding the optimal dosage. However,
none of these algorithms consider heterogeneous groups
of patients.
As the interest in heterogeneous groups of patients
in clinical trials has rapidly grown, clinical trial
designs that consider heterogeneous groups have begun
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to see some attention. In Wages et al. (2015), an
adaptive clinical trial design for heterogeneous groups
was proposed by extending a well-known continual
reassessment method (CRM). However, this work
does not consider a limited budget. Another adaptive
clinical trial algorithm with heterogeneous groups is
developed in Atan et al. (2019), which is based on the
knowledge gradient policy. In this work, the patient
recruitment is determined by considering the budget,
but all groups are assumed to have the same arrival
distribution. Moreover, the primary goal is to label the
effectiveness of treatments, not dose-finding. To the
best of our knowledge, Varatharajah et al. (2018) is the
only work using contextual MAB for clinical trials with
heterogeneous groups, and is is probably the closest to
our work. In the algorithm, a simple contextual MAB
model is applied to clinical trials by considering groups
as contexts. However, the algorithm does not address
several of the challenges associated with heterogeneous
groups such as the differing populations of the groups
and the limited budget.
2 CONTEXTUAL CONSTRAINED
CLINICAL TRIAL (C3T) MODEL
We consider a contextual constrained clinical trial
(C3T) for dose-finding with S subgroups (contexts) over
a time-horizon, T , and limited budget, B, indicating
the maximum number of patients that can be admit-
ted into the trial. The set of subgroups is defined as
S = {1, 2, ..., S}. We consider K candidate doses, with
the set of candidate doses given by K = {1, 2, ...,K}.
The efficacy, Xs,k , and toxicity, Ys,k , of dose k for sub-
group s1 are modelled as Bernoulli random variables
with unknown parameters qs,k and ps,k respectively.
Xs,k = 1 indicates that dose k is effective for subgroup
s and Ys,k = 1 indicates that dose k is unsafe for sub-
group s. We define a dose to be unsafe for subgroup s
if the expected toxicity (ps,k) for subgroup s exceeds
a pre-defined toxicity threshold ζ , which is referred to
as the MTD (maximum tolerated dose) threshold in
the clinical trial literature. We also define a minimum
efficacy threshold, θ, below which we do not wish to
administrate treatment because the efficacy is too low.
For ps,k , we introduce the logistic dose-toxicity model
ps,k(a) =
(
tanhuk+1
2
)a
, as in O’Quigley et al. (1990),
where uk is an actual dose level of dose k and a is
a parameter used for all doses. Then, due to the
monotonicity of the dose-toxicity model, we can parti-
tion doses into safe/unsafe doses as {ps,1, ..., ps,Us } and
{ps,Us+1, ..., ps,K }, where Us = max{k ∈ K : ps,k < ζ }.
1For ease of exposition, we use “subgroup s” and “patient
in subgroup s” interchangeably in the rest of the paper.
At the beginning of each round, t, of the clinical trial, a
patient arrives. We denote the subgroup of the patient
in round t by H(t) ∈ S. The arrival rate of the patients
in each subgroup s is given by ξs. Then, the probability
of the patient in round t being from subgroup s is
given by pis = P(H(t) = s) = ξs∑
s∈S ξs
. For the observed
subgroup H(t), an agent of the clinical trial chooses
a dose k ∈ {0} ∪ K, where “0” represents a “no-dose”
action corresponding to the agent skipping the new
patient. We denote the dose allocated in round t by
I(t). Let Xt , Yt , and Zt be the efficacy, toxicity, and cost
in round t, respectively. When I(t) ≥ 1, we have Xt =
XH(t),I (t), Yt = YH(t),I (t), and Zt = 1 (we will generalize
this to heterogeneous costs across subgroups in Section
4.1). When I(t) = 0, we have no efficacy or toxicity
and the cost Zt = 0. The clinical trial ends when the
budget is exhausted or at the end of time-horizon T .
3 C3T WITH LIMITED BUDGET
3.1 Problem Formulation
Let Π be a bandit algorithm that maps historical
observations, {(Xτ,Yτ,H(τ), I(τ)}t−1τ=1, and the current
subgroup, H(t), to a dose I(t) ∈ {0} ∪ K. We define
the average toxicity of subgroup s to be SΠ,s(T, B) =
E
[ ∑T
t=1 I{H(t)=s}Yt∑T
t=1 I{H(t)=s}I{I (t),0}
]
. We define the total expected
cumulative efficacy as EΠ(T, B) = E
[∑T
t=1 Xt
]
. To
make a recommendation, the MTD threshold and min-
imum efficacy threshold should be considered. We
define the set of candidate doses for subgroup s by
Ks = {k ∈ K : qs,k ≥ θ, ps,k ≤ ζ }. We define the opti-
mal dose-to-recommend for subgroup s by
k∗s =
{
argmaxk∈Ks qs,k, if Ks , ∅,
0, otherwise.
(1)
We define the recommended dose to subgroup s at the
end of the clinical trial as kˆ∗s(T, B). Then, the dose
recommendation error can be written as DΠ(T, B) =∑
s∈S E
[
I[kˆ∗s(T, B), k∗s]
]
. Our C3T problem of minimiz-
ing the dose recommendation error while satisfying the
budget and safety constraints is formally presented as
minimize DΠ(T, B)
subject to P
[
SΠ,s(T, B) ≤ ζ
] ≥ 1 − δs, ∀s ∈ S (2)∑T
t=1 Zt ≤ B.
where δs is the maximum probability with which the
toxicity for subgroup s can exceed the MTD threshold.
3.2 Addressing the Budget Constraint
In clinical trials with a single subgroup, maximizing
the cumulative efficacy with the well-known principle
of optimism in the face of uncertainty is also effective
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to recommend dose (Aziz et al., 2019). Such objective
makes the agent more frequently choose the doses that
are more likely to be the optimal dose. The dose recom-
mendation accuracy is improved since the accuracy for
any dose depends primarily on the number of patients
that were given that dose. Since patients are more
likely to receive the optimal dose, the accuracy of the
optimal dose is better. However, in the case of multiple
subgroups and limited budget, maximizing the cumu-
lative efficacy is no longer effective at recommending
doses across all subgroups due to the varying efficacies
and arrival rates. For example, if one subgroup has
much higher efficacy than others, the optimal strategy
for the agent would involve skipping all patients that
arrive from subgroups other than the one with the
highest efficacy. Little will therefore be learned about
the response of other subgroups to the drug, resulting
in a poor learning performance. Hence, in each round,
the agent should decide to skip the new patient or not
based also on the estimation accuracy for the patient’s
subgroup, remaining budget, and remaining time.
We consider an oracle problem with budget B and
time-horizon T to highlight how to address the bud-
get constraint. We assume S subgroups with different
arrival rates pis, s = 1, ..., S. Each subgroup s has an
arbitrary expected reward d∗s . For convenience, we
assume d∗1 > d
∗
2 > ... > d
∗
S. In general, the expected
rewards d∗s are unknown to the agent. However, we
begin by considering an oracle agent that knows d∗s and
has only two actions: skip or accept the patient. In
each round t, the agent will determine whether to skip
the new patient or not based on the remaining rounds
τ = T − t + 1 and the remaining budget bτ .
Although the oracle problem seems simple, it is known
to be computationally intractable (Wu et al., 2015).
We thus approximate this problem as a linear program
(LP). We first relax the problem by substituting the
hard budget constraint with an average budget con-
straint using ρ = BT . We define the probability that
the agent does not skip a patient in subgroup s by ψs,
and write ψ = {ψ1, ψ2, ...ψS}. We now formulate the
following LP problem:
maximize
ψ
∑
s∈S
ψspisd∗s subject to
∑
s∈S
ψspis ≤ ρ. (3)
The optimal solution of this problem can be easily
derived:
ψs(ρ) =

1, if 1 ≤ s ≤ s˜(ρ),
ρ−ηs˜(ρ)
pis˜(ρ)+1
, if s = s˜(ρ) + 1,
0, if s > s˜(ρ) + 1,
(4)
where ηs =
∑s
s′=1 pis′ (with the convention that η0 = 0)
and s˜(ρ) = max{s ∈ S ∪ {0} : ηs ≤ ρ}.
We can adapt this policy to our more general problem
by deciding to skip a patient or not by replacing d∗s and
ρ in (3) with the estimated recommendation accuracy
or estimated efficacy and the remaining average budget
ρτ =
bτ
τ , respectively.
3.3 C3T-Budget
In Algorithm 1, we propose a bandit solution for the
budget-limited C3T problem in (2) which we call C3T-
Budget. As noted above, when there is only 1 subgroup,
maximizing the cumulative efficacy using the optimism
principle is effective for recommending dose. Thus, in
the algorithm, the dose for each subgroup is chosen
according to the upper confidence bound (UCB) prin-
ciple using the estimated efficacy and toxicity of the
subgroup. On the other hand, the decision to skip
a patient is based on how convincing the estimated
efficacy of the chosen dose for each subgroup is.
Algorithm 1 C3T-Budget
1: Input: Time-horizon T , budget B, subgroup arrival
distributions pis’s, φ for credible intervals
2: Initialize: τ = T , b = B, t = 1, αBeta
s,k
(0) = 1, βBeta
s,k
(0) =
1, ∀s ∈ S, ∀k ∈ K.
3: while t ≤ T do
4: aˆs(t) ←
∑K
k=1 aˆs,k (t−1)Ns,k (t−1)
Ns (t−1) , ∀s ∈ S
5: Ks(t)= {k ∈K : qˆs,k (t)≥ θ, ps,k (aˆs(t)+αs(t)) ≤ ζ }, ∀s∈S
6: if b > 0 then
7: if NH(t)(t) ≤ K then
8: Sample each dose once I(t) = NH(t)(t)
9: else
10: k∗s (t) ← argmaxk∈Ks (t) qˆs,k (t), ∀s ∈ S
11: Calculate B∗s (t) as in (5)
12: Obtain ψˆ (b/τ)’s by solving the LP problem
in (3) with ordered B∗s (t)’s
13: Allocate dose
I(t)=
{
k∗
H(t)(t), with probability ψˆH(t)(b/τ),
0, otherwise.
14: end if
15: end if
16: Observe the efficacy Xt and toxicity Yt
17: Update τ, b, Ns(t), Ns,k (t), q¯s,k (t), qˆs,k (t), p¯s,k (t),
αBeta
s,k
(t), βBeta
s,k
(t)
18: aˆs,k (t)←argmina |ps,I (t)(a)−p¯s,I (t)(t)|, ∀s ∈ S, ∀k ∈ K
19: t = t + 1
20: end while
21: Output: Recommended dose
kˆ∗s =
{
argmaxk∈K′s (T ) q¯s,k, if K ′s(T) , ∅,
0, otherwise
, ∀s ∈ S
We define the empirical efficacy estimation of dose k for
subgroup s at round t by q¯s,k(t) =
∑t
τ=1 I{H(τ)=s,I (τ)=k }Xτ
Ns,k (t) ,
where Ns,k(t) is the number of times that dose k has
been allocated to subgroup s up to round t (i.e.,
Ns,k(t) = ∑tτ=1 I{H(τ) = s, I(τ) = k}). Similarly, we
define the empirical toxicity estimation of dose k for
subgroup s at round t by p¯s,k(t) =
∑t
τ=1 I{H(τ)=s,I (τ)=k }Yτ
Ns,k (t) .
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Then, the UCB of qs,k at round t is defined as
qˆs,k(t) = q¯s,k +
√
c log Ns (t)
Ns,k (t−1) , where Ns(t) is the number of
times that subgroup s has arrived up to round t (i.e.,
Ns(t) = ∑tτ=1 I{H(τ) = s}). The confidence interval
as for the dose-toxicity model of subgroup s is given
by αs(t) = CK
(
log 2Kδs
2Ns (t)
) γ
2
, where C and γ are hyper-
parameters of our model. Details of hyper-parameter
selection are given in the supplementary material.
In each round t, the algorithm constructs a set of can-
didate doses for each subgroup s, Ks, by considering
the estimated expected efficacy and toxicity of each
dose for the subgroup and using the UCB principle.
Among the candidate doses, the algorithm selects the
estimated optimal dose in round t, k∗s(t), which has the
largest UCB of the expected efficacy for subgroup s,
as k∗s(t) = argmaxk∈Ks (t) qˆs,k(t). Then, the agent deter-
mines whether the patient in round t is to be skipped
or not by considering how convincing the estimation
of the efficacy of k∗s is. To do this, we use the credible
interval of the estimation of q¯s,k .
We adopt a Bayesian approach to estimate q¯s,k . We
first consider a uniform distribution (i.e., Beta(1, 1))
as the prior for qs,k . Then, the maximum posterior
estimation of qs,k becomes the empirical efficacy esti-
mation q¯s,k . This allows us to combine the Bayesian
approach and the UCB principle without conflict. We
define the parameters of the prior distribution of qs,k
in round t as αBeta
s,k
(t) and βBeta
s,k
(t). Then, at the
end of round t, we update the posterior distribution
of qH(t),I (t) as αBetaH(t),I (t)(t) = αBetaH(t),I (t)(t − 1) + X(t) and
βBeta
H(t),I (t)(t) = βBetaH(t),I (t)(t − 1) + (1 − X(t)). By using the
posterior distribution of qs,k , we can obtain a credible
interval for a given probability φ. Let f (φ, αBeta, βBeta)
be a function that calculates the interval length to
achieve the probability φ. We then define the expected
improvement of the credible interval for an additional
patient in subgroup s with dose k as
Bs,k = q¯s,k( f (φ, αBetas,k , βBetas,k )− f (φ, αBetas,k + 1, βBetas,k ))
+ (1−q¯s,k)( f (φ, αBetas,k , βBetas,k )− f (φ, αBetas,k , βBetas,k +1)).(5)
This value quantifies the improvement in estimation
accuracy provided by including an additional patient
from subgroup s into the trial. Thus, we can use it to
determine which subgroups should be skipped to max-
imize the dose-recommendation accuracy. Specifically,
in round t, we rearrange the set {Bs,k∗s (t)(t) : s = 1, ..., S}
in descending order. The algorithm then solves
the LP problem in (3), substituting d∗s and ρ with
Bs,k∗s (t)(t) and ρτ , respectively, and obtains a vector of
probabilities ψˆ(ρτ). Finally, at the end of the clinical
trial, the dose recommended to subgroup s is given by
kˆ∗s(T, B) =
{
argmaxk∈Ks (T ) q¯s,k, if K ′s(T) , ∅,
0, otherwise.
3.4 Extension: C3T-Budget-E
In a clinical trial where the budget is particularly lim-
ited, identifying even just one subgroup for which the
drug is effective can be more important than under-
standing its effect on the whole population of interest.
Trying to learn on the whole population might lead
to the responses all subgroups being poorly estimated
and the drug failing to progress at all. Thus, a differ-
ent problem formulation is used when the budget is
small, allowing the trial to focus on subgroups with
high efficacies:
maximize EΠ(T, B)
subject to P
[
SΠ,s(T, B) ≤ ζ
] ≥ 1 − δs, ∀s ∈ S (6)∑T
t=1 Zt ≤ B.
where we have simply substituted the objective function
DΠ(T, B) in (2) with EΠ(T, B). With this formulation,
the agent tries to accurately recommend doses for sub-
groups with high efficacies while also achieving high
total cumulative efficacy.
We now propose a bandit algorithm for the budget-
limited C3T problem in (6) to maximize the total cu-
mulative efficacy called C3T-Budget-E. This algorithm
focuses more on the subgroups that have high efficacies,
which might result in inaccurate dose recommendation
for subgroups with low efficacies.
C3T-Budget-E is a modified version of C3T-Budget.
The key difference is that the decision to skip a patient
is based on the expected efficacy of each subgroup
rather than the expected improvement of the credible
interval. Hence, in C3T-Budget-E, the parameters
for the Bayesian posterior distribution are not used.
Specifically, the algorithm first finds the largest UCB of
the estimated expected efficacy for subgroup s in round
t as qˆ∗s(t) = maxk∈Ks (t) qˆs,k(t). Then, it re-orders {qˆ∗s(t) :
s = 1, ..., S} and obtains the vector of probabilities
ψˆ(ρ(t)) by solving the LP problem in (3) with the
ordered qˆ∗s(t)’s and ρτ . A detailed description of C3T-
Budget-E can be found in the supplementary material.
3.5 Theoretical Analysis
We now analyze the theoretical performance of the
proposed algorithms, which we refer to collectively as
C3T-Budgets (i.e., C3T-Budget and C3T-Budget-E).
All proofs can be found in the supplementary material.
We begin by bounding the safety constraint violation.
Theorem 1. For any given T , the average toxicity of
subgroup s observed from C3T-Budgets satisfies
P
[∑Ns (T )
t=1 ps,I (N−1s (t))
Ns(T) − ζ ≤ C
γ
]
≥ 1 − δs,
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for an arbitrary  > 0, where C and γ are hyper-
parameters (described in the supplementary material).
C3T-Budget and C3T-Budget-E therefore satisfy the
safety constraints given in (2) and (6), respectively.
The following theorem bounds the recommended dose
error of C3T-Budgets.
Theorem 2. The probability that C3T-Budgets rec-
ommends an incorrect dose for subgroup s is bounded
according to
P
[
kˆ∗s , k
∗
s
]
≤ MR1e−MR2Ns (T )
where MR1 and MR2 are non-negative constants (pro-
vided in the supplementary material).
Theorem 2 indicates that the accuracy of the recom-
mended dose depends strongly on the number of sam-
ples accepted in each subgroup. The worst-case regret
bound for the total efficacy of C3T-Budget-E is pro-
vided in the supplementary material. We also corrobo-
rate these theoretical behaviors of C3T-Budgets with
empirical results in the experiments section.
4 DISCUSSION
4.1 Heterogeneous Costs for Subgroups
In practice, the cost of recruiting a patient into a clini-
cal trial may be different across subgroups. To address
this, an extension of C3T-Budgets is needed in which
heterogeneous costs for different subgroups can be ac-
counted for. Let cs be a non-negative cost associated
with subgroup s that occurs when any dose is allocated
to a patient in subgroup s. We can then reformulate
the LP problem in (3) as
maximize
ψ
∑
s∈S
ψspi
′
s
d∗s
cs
subject to
∑
s∈S
ψspi
′
s ≤ ρ,
where pi′s = piscs. Then we apply C3T-Budget as in
Algorithm 1 by substituting pi′s and B∗s(t)/cs (q∗s(t)/cs
for C3T-Budget-E) into line 12, whenever appropriate.
4.2 Sequential Patient Recruitment
In clinical trials, a “complete” list of candidate patients
is often given in advance, and then patients are sequen-
tially selected from among the candidate patients. For
this sequential patient recruitment, C3T-Budgets can
be applied. Let pis be proportion of candidate patients
that belong to subgroup s. Based on pis, a patient
arrival sequence can be virtually generated and the
problem reduces to the same problem as originally dis-
cussed, so that C3T-Budgets can be applied to the
virtually generated arrival sequence.
5 EXPERIMENTS
In this section, we demonstrate the performance of our
algorithm through a series of experimental results.2 We
consider a dose-finding clinical trial with 3 subgroups
(i.e. S = 3) and 6 doses (i.e. K = 6). In the clinical trial,
400 patients can be recruited in total (i.e., B = 400)
and a maximum of 1200 rounds can be performed (i.e.
T = 1200). The arrival distributions for each of the 3
subgroups is given by pi1 =
5
12 , pi2 =
4
12 , and pi3 =
3
12 .
The MTD threshold is set to be 0.35 (i.e. ζ = 0.35)
and the minimum efficacy threshold is set to be 0.2 (i.e.
θ = 0.2). The expected efficacy, qs,k , and expected tox-
icity, ps,k , of each dose for each subgroup are provided
in Table 2. We highlight the optimal dose for each
subgroup in bold. Note that there is no optimal dose
for subgroup 1 as in (1) since their expected efficacy
is below the minimum efficacy threshold (and so the
optimal action is to not treat them at all). All exper-
imental settings are similar to Riviere et al. (2018);
Aziz et al. (2019) and we use them unless otherwise
mentioned. All experiments are repeated 500 times
and the results are averaged.
Table 2: Settings of Synthetic Model
S Type Characteristics
1
q1,k ’s 0.01 0.02 0.05 0.1 0.1 0.1
p1,k ’s 0.01 0.01 0.05 0.15 0.2 0.45
2
q2,k ’s 0.1 0.2 0.3 0.5 0.6 0.65
p2,k ’s 0.01 0.05 0.15 0.2 0.45 0.6
3
q3,k ’s 0.2 0.5 0.6 0.8 0.84 0.85
p3,k ’s 0.01 0.05 0.15 0.2 0.45 0.6
For benchmarks, we modify the following baseline al-
gorithms to include contexts as in Zhou (2015) and
implement them for contextual clinical trials: 3+3
design (Storer, 1989), Contextual UCB (Auer et al.,
2002; Varatharajah et al., 2018), Contextual KL-UCB
(Garivier and Cappe´, 2011; Varatharajah et al., 2018),
and Contextual independent Thompson sampling (TS)
(Aziz et al., 2019). The details of the algorithms are
provided in the supplementary material.
5.1 Recommended Dose Error Rates
In Table 3, we report the recommended dose error
rate of each algorithm both as an average across all
subgroups (Total) and individually for each subgroup
(SG1, SG2, SG3). From the results, we can see that
C3T-Budget achieves the lowest total error rate, with a
lower error within each subgroup than all benchmarks
except: C-UCB and C-Indep-TS whose error is lower
2The implementation of C3T-Budgets is available at:
https://bitbucket.org/mvdschaar/mlforhealthlabpub/
src/master/alg/c3t budgets
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in SG1 due to the fact that SG1 has the highest arrival
rate and C-UCB and C-Indep-TS recruits all patients,
C3T-Budget instead makes better use of the budget
to balance the learning across all subgroups; and C3T-
Budget-E, which notably only achieves lower error on
SG3, the subgroup with the highest efficacy. This is
exactly as we would expect, since the goal of C3T-
Budget-E is to focus on the highest efficacy subgroups,
thus resulting in better estimations of the optimal
dose for those subgroups. The superior performance
of C3T-Budget is due to its capability to effectively
recruit patients from subgroups that will best improve
recommended dose errors while remaining within the
budget constraint. This will be investigated further in
Section 5.4.
Table 3: Recommended Dose Error Rates
Algorithm
Errors
SG 1 SG 2 SG 3 Total
C3T-Budget 0.050 0.056 0.036 0.047
C3T-Budget-E 0.204 0.138 0.020 0.121
C-UCB 0.012 0.414 0.316 0.247
C-KL-UCB 0.204 0.440 0.368 0.337
C-Indep-TS 0.012 0.354 0.372 0.246
C-3+3 0.874 0.746 0.780 0.800
5.2 Safe Dose Estimation Error Rates
We define the type-I and type-II errors for dose safety
as follows: Type-I error occurs when a safe dose is
estimated to be unsafe and type-II error occurs when
an unsafe dose is estimated to be safe. We report these
errors for C3T-Budgets and each of the benchrmark al-
gorithms in Table 4. We see that C3T-Budget achieves
the lowest total error rates. In C3T-Budget, subgroups
are recruited to maximize the confidence of our esti-
mations, which in turn leads to confident estimates of
safe doses.
Table 4: Safe Dose Estimation Error Rates
Algorithm
Errors
Type-I Type-II Total
C3T-Budget 0.0226 0.0198 0.0212
C3T-Budget-E 0.0200 0.0304 0.0252
C-UCB 0.0248 0.0289 0.0268
C-KL-UCB 0.0371 0.0437 0.0404
C-Indep-TS 0.1006 0.0366 0.0686
C-3+3 0.0400 0.1081 0.0741
5.3 Efficacy and Toxicity Per Patient
We now report the efficacy and toxicity per patient for
each algorithm in Table 5. From the results, we can see
that both C3T-Budgets, but particularly C3T-Budget-
E, achieve a much higher efficacy than other algorithms.
In addition, C3T-Budgets achieve a lower toxicity than
other algorithms except for the 3+3 design. Note,
however, that the 3+3 design is designed specifically to
avoid safety violations - it ends when a certain number
of toxicities have occurred. Hence, it naturally has a
low toxicity compared to the bandit algorithms, but
it achieves a much lower efficacy as well as shown in
Table 5 and inaccurately recommends doses as shown
in Table 3.
Table 5: Efficacy and Toxicity Per Patient
Algorithm Efficacy Toxicity
C3T-Budget 0.4975 0.1881
C3T-Budget-E 0.5791 0.1911
C-UCB 0.4154 0.3235
C-KL-UCB 0.3823 0.2621
C-Indep-TS 0.4101 0.3157
C-3+3 0.3081 0.1537
5.4 Recruited Patients for Each Subgroup
and Efficacy Estimation Errors
To understand the recruitment behaviors of C3T-
Budgets and how they relate to efficacy estimation
error, Fig. 1 shows the number of patients recruited
from each subgroup and the mean squared error (MSE)
of the efficacy estimate of the optimal dose in each sub-
group (for subgroup 1, we provide the averaged MSE
of all safe doses since there is no optimal dose) over
time. Note that the recruitment numbers of the other
bandit algorithms are equal to those with pis since they
do not address the budget constraint.
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Figure 1: Number of recruited patients and the MSE
of the efficacy estimation of each subgroup.
From the figure, we can see that both C3T-Budgets
recruit patients independently of the arrival rate of each
subgroup. In C3T-Budget, the patients are recruited to
achieve low enough estimation errors for all subgroups,
demonstrated by the fact that recruitment for subgroup
1 is stopped after the estimation errors of the doses
for subgroup 1 become low enough. C3T-Budget then
starts to recruit more patients from subgroups 2 and 3.
Subgroup 2 ends up having the most patients recruited
for it, due to the fact that the expected efficacy (0.5) of
its optimal dose is more difficult to estimate than those
of subgroups 1 and 3 (0.1 and 0.8, respectively). On
the other hand, C3T-Budget-E recruits more patients
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from subgroup 3 due to it having the highest expected
efficacy. C3T-Budget-E recruits only enough patients
from subgroup 1 to allow for reasonable belief that it
has the lowest expected efficacy. More patients are
recruited from subgroup 2 than from subgroup 1, due
to the fact that it requires more samples to be sure
that the efficacy is lower than that of subgroup 3, but
once the algorithm has confidence that the efficacy is
lower, recruitment slows, in favour of recruiting from
subgroup 3, thus leading to higher estimation error
for subgroup 2. We see from these figures that the
recruitment behavior of C3T-Budget and C3T-Budget-
E are as intended.
5.5 Impact of Budget
In this experiment, we report the recommended dose
error rates and efficacy per patient of each algorithms
while we vary the budget, B, in Fig. 2. Since the
ratio B/T affects C3T-Budgets, we set the time-horizon
T such that the ratio B/T is constant and 1/3. The
results of the 3+3 design are not provided here since
its performance does not depend on the total number
of patients to dose.
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Figure 2: Total recommended dose error rate and effi-
cacy per patient varying the budget.
From Figs. 2a and 2b, we can see that the recom-
mended dose error rates of all algorithms decrease and
the efficacy per patient of all algorithms increases, as
B increases. However, we see that for all B > 80, C3T-
Budget achieves the lowest error, while for B < 80
(i.e. when the budget is particularly limited), we see
that C3T-Budget-E achieves the lowest error. For all
B, we see that C3T-Budget-E achieves the best effi-
cacy. Notably, as B increases, the error of C3T-Budget
drastically decreases and achieves near-zero error when
B ≥ 500. These results clearly demonstrate that C3T-
Budgets do indeed effectively utilize the budget con-
straints unlike the other algorithms.
5.6 Impact of Time Horizon
We show the impact of varying the time-horizon T on
the performance of our algorithm. If the time-horizon
T is set to be the budget B, then C3T-Budgets do not
skip any patients. Thus, C3T-Budget and C3T-Budget-
E become the same algorithm. Note that all the other
algorithms do not depend on the time-horizon T .
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Figure 3: Total recommended dose error rate and effi-
cacy per patient varying the time-horizon.
In Fig. 3, we show the recommended dose error rates
and efficacy per patient of the algorithms when varying
T/B from 1 to 5. From Fig. 3a, we can see that the
recommended dose error rate of C3T-Budget decreases
while that of C3T-Budget-E increases as T/B increases.
As T/B increases, C3T-Budgets can recruit subgroups
more flexibly, since they have more time in which to
“wait” for patients from a more desirable subgroup (they
can afford to skip more patients). Thus, the error rate
of C3T-Budget decreases since it recruits patients that
will best reduce the error. On the other hand, the
increased recruitment policy allows C3T-Budget-E to
focus its recruitment more on subgroup 3 (so that it
achieves high cumulative efficacy), but this in turn
results in a higher error rate for subgroups 1 and 2,
thus resulting in a higher total error. From Fig. 3b, we
can see that as T/B increases, the efficacies of both C3T-
Budgets increase thanks to the increased recruitment
flexibility. From the results, we can see that both error
rate and efficacy are saturated. If T/B is large enough,
even very small arrival rates for a given group can be
accommodated. The limiting factor then becomes the
budget, B, and increasing T/B will have no (or very
little) further effect.
6 CONCLUSION
In this paper, we have studied dose-finding clinical tri-
als with heterogeneous groups and a limited budget.
We proposed C3T-Budget in which, for each group, the
dose with the highest estimated efficacy is chosen, but
the group may be skipped if the algorithm is sufficiently
confident in its current estimation of the efficacy. In
addition, we proposed an extension, C3T-Budget-E,
which is particularly applicable in very low-budget set-
tings, where accurately estimating efficacy for the most
promising subgroups is more important than accurate
estimation for all groups. These designs can effectively
utilize the limited budget to balance the trade-off be-
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tween learning and treatment. We demonstrated that
our proposed algorithms outperform state-of-the-art
algorithms through a series of experiments.
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A PRELIMINARIES
Before providing the proof of the theorems, we introduce some regularity assumptions on the dose-toxicity model
as follows.
Assumption 1. There exist C1,s,k > 0, 1 < γ1,s,k , C2,s,k , and 0 < γ2,s,k ≤ 1 such that |ps,k(a) − ps,k(a′)| ≥
C1,s,k |a − a′ |γ1,s,k and |ps,k(a) − ps,k(a′)| ≤ C2,s,k |a − a′ |γ2,s,k for all s ∈ S, k ∈ K, and a, a′ ∈ A.
We then immediately have the following proposition.
Proposition 1. For ps,k(a), ∀s ∈ S, ∀k ∈ K satisfying Assumption 1,
1. ps,k(a) is invertible;
2. For each s ∈ S, k ∈ K, and d, d ′ ∈ P, we have |p−1
s,k
(d) − p−1
s,k
(d ′)| ≤ C¯1,s,k |d − d ′ |γ¯1,s,k , where ¯γ1,s,k = 1γ1,s,k and
C¯1,s,k = C
− 1γ1,s,k
1,s,k
.
For notational simplicity, we denote C1,s = mink∈K C1,s,k , C2,s = maxk∈K C2,s,k , γ1,s = maxk∈K γ1,s,k , γ2,s =
mink∈K γ2,s,k , γ¯1,s = γ−11,s, and C¯1,s = C
−γ¯1,s
1,s .
B PROOF OF THEOREM 1
From the Hoeffding bound, the following upper bound of the probability is given:
P[aˆ(t) − a∗s > αs(t) + ] ≤ exp(−2Ns(t)(αs(t) + )2).
In addition, the difference between the MTD threshold and the expected toxicity is also bounded as
ps,I (t)(a∗s) − ζ ≤ ps,I (t)(a∗s) −ζ+ζ − ps,I (t)(a∗s − αs(t))
≤ C2,s |a∗s − aˆs(t) + αs(t)|γ2,s .
By rearranging the terms, we have
P
[∑Ns (T )
t=1 pn,I (N−1s (t))(a∗s)
Ns(T) − ζ < Cn,2
γn,2
]
≥ 1 − exp(−2Ns(T)(αs(Ns(T)) + )2)
≥ 1 − δs .
C PROOF OF THEOREM 2
C.1 Case 1: k∗s , 0
We first bound the probability that the recommended dose error for subgroup s occurs with C3T-Budget if k∗s , 0.
The event that the recommended dose error occurs satisfies the following:{
kˆ∗s , k
∗
s
}
⊆ {ps,k∗s (aˆs(T)) > ζ} ∪ {q¯s,k∗s (T) < θ} ∪ {max
k∈Ks
q¯s,k(T) , k∗s
}
.
Thus, the probability of the recommended dose error for subgroup s can be bounded as
P
[
kˆ∗s , k
∗
s
]
≤ P [ps,k∗s (aˆs(T)) > ζ ] + P [q¯s,k∗s (T) < θ] + P [max
k∈Ks
q¯s,k(T) , k∗s
]
.
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Then, we can bound the probability by obtaining the bound for each term.
Bound of First Term: The probability in the first term can be transformed and bounded as
P
[
aˆs(Ns(T)) < p−1s,k∗s (ζ)
]
≤ P [|a∗s − aˆs(Ns(T))| > ΓUs ]
≤
∑
k∈K
P
[pˆs,k(Ns(T)) − ps,k(a∗s) > ( ΓUsNs(T)Ns,k(T)C¯1,sK
)γ1,s ]
≤
∑
k∈K
2 exp
(
−2Ns,k(T)
(
ΓUsNs(T)
Ns,k(T)C¯1,sK
)γ1,s )
(7)
≤ 2K exp
(
−2
(
ΓUs
C¯1,sK
)γ1,s
Ns(T)
)
, (8)
where ΓUs = |a∗s − p−1s,k(ζ)|. The inequality in (7) follows from the Hoeffding’s inequality and the inequality in (8)
follows from the regularity assumption γ1,s > 1.
Bound of Second Term: From the Chernoff-Hoeffding’s inequality, we have
P
[
q¯s,k∗s (T) < θ
]
= P
[
q¯s,k∗s (T) < qs,k∗s − (qs,k∗s − θ)
]
≤ exp
(
−2Ns,k∗s (T)∆2s,θ
)
≤ exp
(
− 8
25
cNs(T)∆2s,θ
∆2s∗
)
, (9)
where ∆s∗,θ = |qs,k∗s − θ | and
∆s∗ =
{
9(mink∈K,k,k∗s qs,k∗s − qs,k), if k∗s = maxk∈K {qs,k},
maxk∈K {qs,k} − qs,k∗s , otherwise.
The inequality in (9) follows from the lemmas in (Audibert et al., 2010).
Bound of Third Term: The bound of the third term can be obtained by following the proof of Theorem 1 in
(Audibert et al., 2010). The third term is bounded as
P
[
max
k∈Ks
q¯s,k , k∗s
]
≤ 2Ns(T)K exp
(
−2cNs(T)
25
)
. (10)
Total Bound: From the bounds in (8), (9), and (10), we can bound the probability of the recommended dose
error for subgroup s as
P
[
kˆ∗s , k
∗
s
]
≤ exp (−M(1a)Ns(T)) + 2K (exp (−M(1b)Ns(T)) + Ns(T) exp (−M(1c)Ns(T)) ) ,
where M(1a) = 825
c∆2s, θ
∆2
s∗
, M(1b) = 2
(
ΓUs
C¯1,sK
)γ1,s
, and M(1c) = 2c25 .
C.2 Case 2: k∗s = 0
For the case with k∗s = 0, we can bound the probability of the recommended dose error for subgroup s similar to
Case 1. We have {
kˆ∗s , 0
}
⊆
⋃
k∈K
{
ps,k(aˆs(T)) ≤ ζ
} ∪ ⋃
k∈K
{
q¯s,k(T) ≥ θ
}
and
P
[
kˆ∗s , 0
]
≤
∑
k∈K
P
[
ps,k(aˆs(T)) ≤ ζ
]
+
∑
k∈K
P
[
q¯s,k(T) ≥ θ
]
.
Similar to Case 1, we can bound the probability as
P
[
kˆ∗s , 0
]
≤ K exp (−M(2a)Ns(T)) + 2K2 exp (−M(2b)Ns(T)) ,
where M(1a) = 825
c∆2
s∗θ
∆2
s∗
, M(1b) = 2
(
Γ¯Us
C¯1,sK
)γ1,s
, ∆¯s∗,θ = maxk∈K |θ − qs,k |, ∆s∗ = maxk∈K {qs,k} −mink∈K {qs,k}, and
Γ¯Us = maxk∈K ΓUs .
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C.3 Recommended Dose Error Bound
Finally, we have the theorem with MR1 = max{1 + 2K + Ns(T),K + 2K2} and MR2 =
min{M(1a),M(1b),M(1c),M(2a),M(2b)}.
D Worst-Case Reget Bound For Total Efficacy of C3T-Budget-E
To evaluate C3T-Budget-E, we compare its performance to that of an algorithm with the complete knowledge of
qs,k ’s and ps,k ’s called an oracle algorithm. We denote the expected total cumulative efficacy achieved by the
oracle algorithm by E∗(T, B). Then, the regret of C3T-Budget-E is defined as
R(T, B) = E∗(T, B) − E(T, B), (11)
where E(T, B) is the expected total cumulative efficacy. Then, we provide the efficacy regret bound of C3T-Budget.
Theorem 3. Given a fixed ρ ∈ (0, 1), the worst-case regret of C3T-Budget-E is bounded as
R(T, B) ≤ T δ¯∆¯ + q∗1
√
ρ(1 − ρ)T + ME logT +O(1),
where ME is a non-negative constant (provided in our supplementary material).
Proof. For the regret bound of C3T-Budget-E, we first define the optimal value of the LP problem that can be
obtained by solving the LP problem with q∗s ’s (see (3) in our main paper) as
v(ρ) =
s˜(ρ)∑
s=1
pisd∗s + ψs˜(ρ)+1(ρ)pis˜(ρ)+1d∗s˜(ρ)+1.
This optimal value v(ρ) can be considered the maximum expected reward in a single round with average budget
ρ. Thus, using v(ρ), we can bound the total expected cumulative efficacy of the oracle E∗(T, B) as the following
lemma.
Lemma 1. (Wu et al., 2015) If the time-horizon and budget are given by T and B, respectively, then we have
Eˆ(T, B) = Tv(ρ) ≥ E∗(T, B).
Then, the upper bound of the expected cumulative efficacy of the oracle E∗(T, B) as follows.
R(T, B) = E∗(T, B) − E(T, B)
≤ Eˆ(T, B) − E(T, B)
= Tv(ρ) −
∑
s∈S
∑
k∈K
qs,kE[Ns,k(T)].
From the regret using Eˆ(T, B), we can partition the regret according to the source of regret as follows:
R(T, B) = Tv(ρ) −
∑
s∈S
∑
k∈K
qs,kE[Ns,k(T)]
=
∑
s∈S
∑
k∈K
∆
(s)
s,k
E[Ns,k(T)] + Tv(ρ) −
∑
s∈S
q∗sE[Ns(T)]
=
∑
s∈S
∑
k∈K
∆
(s)
s,k
E[Ns,k(T)]︸                        ︷︷                        ︸
=R(1)(T,B)
+
T∑
t=1
E
[
v(ρ) −
∑
s∈S
ψˆs(ρ(t))pisq∗s
]
︸                                    ︷︷                                    ︸
=R(2)(T,B)
.
Recall that ∆(s
′)
s,k
is the difference between the optimal expected efficacy of subgroup s′ and the expected efficacy
of subgroup s with dose k, ∆(s
′)
s,k
= qs′ − qs,k . The decomposed regret R(1) represents the regret due to taking
suboptimal doses and the other decomposed regret R(2) represents the regret due to ordering errors in subgroups. It
is worth noting that in R(2), it is supposed that the optimal doses are chosen. Finally, the regret of C3T-Budget-E
is bounded as
R(T, B) ≤ R(1)(T, B) + R(2)(T, B).
Then, we can bound the regret of C3T-Budget by obtaining the bound of each regret.
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D.1 Bound of R(1)
We first bound the first part of the regret, R(1). In C3T-Budget-E, the set of candidate recommended doses is
constructed in each round and the dose is chosen among the doses in the set. Thus, taking the suboptimal doses
can occur due to not only the inaccurate estimation of the efficacy but also the inaccurate estimation of the
toxicity. To reflect this, we decompose the regret R(1) into two parts according to whether the optimal dose is
included in the set of the candidate doses or not as follows.
R(1)(T, B) =
T∑
t=1
∑
s∈S
I{H(t) = s}P[k∗s < Ks(t)]∆¯s︸                                         ︷︷                                         ︸
=R(1a)(T,B)
+
T∑
t=1
∑
s∈S
I{H(t) = s}P[k∗s ∈ Ks(t)]Rs,2(t)︸                                               ︷︷                                               ︸
=R(1b)(T,B)
,
where ∆¯s = maxk∈K ∆
(s)
s,k
.
Bound of R(1a)(T, B): We bound the regret R(1a). Since the event {k∗s < Ks(t)} can be bounded by {ps,k∗s (aˆs(t) −
αs(t)) > ζ } ∪ {qˆs,k∗s (t) < θ}, we can bound the regret R(1a) as
R(1a)(T, B) ≤
T∑
t=1
∑
s∈S
I{H(t) = s} (P[ps,k∗s (aˆs(t) − αs(t)) > ζ] + P[qˆs,k∗s (t) < θ]) ∆¯s
=
T∑
t=1
∑
s∈S
I{H(t) = s}P[ps,k∗s (aˆs(t) − αs(t)) > ζ]∆¯s︸                                                           ︷︷                                                           ︸
=R(1a−1)(T,B)
+
T∑
t=1
∑
s∈S
I{H(t) = s}P[qˆs,k∗s (t) < θ]∆¯s︸                                          ︷︷                                          ︸
=R(1a−2)(T,B)
.
We first bound R(1a−1)(T, B). In the following lemma, we show that the safe dose for each subgroup (i.e., the
toxicities of the dose levels are below the MTD threshold) are included in the set of the candidate doses with
high probability.
Lemma 2. For each subgroup s, P[ps,k(aˆs(t) + αs(t)) > ζ] ≤ δs, for any ps,k(a∗s) ≤ ζ .
Proof. We have
P[aˆs(t) + αs(t) < a∗s] = P[a∗s − aˆs(t) > αs(t)]
≤
∑
k∈K
P
[
| pˆs,k(t) − ps,k(a∗s)| >
(
αs(t)Ns(t)
Ns,k(t)C¯s,1K
)γs,1 ]
≤
∑
k∈K
2 exp
(
−2Ns,k(t)
(
αs(t)Ns(t)
Ns,k(t)C¯s,1K
)2γs,1 )
(12)
≤ 2K exp
(
−
(
αs(t)
C¯s,1K
)2γs,1
Ns(t)
)
= δs
The inequality in (12) follows from the Hoeffding’s inequality. 
From this lemma, the probability that the event {ps,k∗s (aˆs(t) − αs(t)) > ζ } occurs is bounded by δs since the set of
the candidate doses for subgroup s is constructed by {k ∈ K : ps,k(aˆs(t) + αs(t)) ≤ ζ } in C3T-Budget-E. Then, the
regret R(1a−1) can be simply bounded as
R(1a−1)(T, B) ≤
∑
s∈S
Ns(T)δs∆¯s
≤ T δ¯∆¯,
where δ¯ = maxs∈S δs and ∆¯ = maxs∈S ∆¯s.
We bound the regret R(1a−2)(T, B). For the minimum efficacy threshold, we have the following lemma.
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Lemma 3. Let For each subgroup s, P[qˆs,k∗s (t) < θ] ≤ Ns(t)−2c.
Proof. We have
P[qˆs,k∗s (t) < θ] ≤ P
[
q¯s,k∗s (t) < qs,k∗s −
√
c log Ns(t)
Ns,k∗s (t)
]
≤ Ns(t)−2c
The first inequality follows from the fact qs,k∗s ≥ θ and the second inequality follows from the Chernoff-Hoeffding
inequality. 
Then, for c ≥ 12 , the regret R(1a−2)(T, B) is bounded as
T∑
t=1
∑
s∈S
I{H(t) = s}P[qˆs,k∗s (t) < θ]∆¯s ≤
T∑
t=1
∑
s∈S
I{H(t) = s}Ns(t)−2c∆¯s
≤ S
T∑
t=1
t−2c∆¯
≤ S log(T)∆¯ (13)
In summary, we have the bound of R(1a)(T, B) as following.
R(1a)(T, B) ≤ (T δ¯ + S logT)∆¯
Bound of R(1b)(T, B):We now bound the regret R(1b). In this case, the optimal dose is included in the set of the
candidate doses. Then, the error occurs when the suboptimal doses are chosen in the set due to the inaccurate
parameter estimation aˆs and the inaccurate efficacy estimation. To bound this, in the following lemma, we show
that the unsafe dose for each subgroup (i.e., the toxicities of the dose levels exceed the MTD threshold) are
excluded from the set of the candidate doses with high probability.
Lemma 4. Let Γs = mink∈K |a∗s − p−1s,k(ζ)| and
αs(t) = C¯s,1K
(
log 2Kδs
2Ns(t)
) γ¯s,1
2
.
For each subgroup s, if Ns(t) ≥ t(1b)s = 12
(
C¯s,1K
Γs−
)2γs,1
log 2Kδs , then we have P[ps,k(aˆs(t)+αs(t)) ≤ ζ] ≤ exp(−2Ns(t)2),
for any ps,k(a∗s) > ζ .
Proof. From the Hoeffding’s inequality, we have
αs(t) ≤ p−1s,k(ζ) − a∗s −  = ∆s,k − ,
where ∆s,k = |a∗s − p−1s,k(ζ)|. With the definition of αs(t), we can conclude the lemma. 
Let N−1s (τ) = mint {t : Ns(t) = τ} which represents the round index at which the τ-th patient of subgroup s arrives.
Then, we can bound the regret R(1b) as
R(1b) ≤
∑
s∈S
t(1b)s + (K −Us)
Ns (T )∑
t=1
exp(−2t2) +
Ns (T )∑
t=ts+1
∑
k:ps,k (a∗s )≤ζ
I{I(N−1s (t)) = k}

≤
∑
s∈S
t(1b)s +
K −Us
22
+
∑
k:ps,k (a∗s )≤ζ
c logT
∆
(s)
s,k

≤ t¯(1b) + K −U
22
+
∑
s∈S
∑
k:ps,k (a∗s )≤ζ
c logT
∆
(s)
s,k
,
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where t¯(1b) = maxs∈S t
(1b)
s and U = mins∈S Us.
Bound of R(1)(T, B): Finally, from the bounds of R(1a) and R(1b), we have the regret bound of R(1) as following:
R(1)(T, B) ≤ (T δ¯ + S logT)∆¯ +
∑
s∈S
∑
k:ps,k (a∗s )≤ζ
c logT
∆
(s)
s,k
+O(1). (14)
D.2 Bound of R(2)
We now bound the second part of the regret, R(2). Recall that the regret R is decomposed into two parts: the
regret due to taking suboptimal doses R(1) and the regret due to ordering errors in subgroups R(2). Thus, in here,
we do not have to consider the suboptimal doses and consider the ordering errors only.
In Wu et al. (2015), the regret due to the ordering error is analyzed. Compared with the case that is analyzed, we
additionally consider the safety constraint. However, we can follow the analysis on the regret due to the ordering
error in Wu et al. (2015) for the bound of R(2) since the safety constraint reduces the ordering errors by excluding
the unsafe doses which is not the optimal doses. Thus, we can provide the regret bound of R(2) by using the
analysis.
Before providing the regret bound, we define some boundary cases according to ρ and ηs’s since the bound
depends on them. We first define a non-boundary case for a given fixed ρ ∈ (0, 1) as a case in which ρ , ηs for
any s ∈ S, and define a boundary case for a given fixed ρ ∈ (0, 1) as a case in which ρ = ηs for some s ∈ S. Then,
by applying the analysis on our algorithm, we have the regret bounds on the following lemma.
Lemma 5. (Wu et al., 2015) Given a fixed ρ ∈ (0, 1), the regret R(2)(T, B) is bounded as follows:
(1) For the non-boundary case,
R(2)(T, B) ≤ [q¯∗ + v(ρ)]M (2)
nb
logT +O(1)
(2) For the boundary case,
R(2)(T, B) ≤ q∗1
√
ρ(1 − ρ)T + M (2)
b
logT +O(1)
where q¯∗ =
∑
s∈S pisq∗s,
M (2)
nb
=
s˜(ρ)∑
s=1
∑
k∈K
27
2gnb
s˜(ρ)+1
[
∆
(s)
s˜(ρ)+1,k
]2 + S∑
s=s˜+2
∑
k∈K
27
2gnbs
[
∆
(s˜+1)
s,k
]2 + 2SK,
M (2)
b
=
s˜(ρ)−1∑
s=1
∑
k∈K
27
2gb
s˜(ρ)
[
∆
(s)
s˜(ρ),k
]2 + S∑
s=s˜+1
∑
k∈K
27
2gbs
[
∆
(s˜)
s,k
]2 + 2SK,
gnbs = min
{
pis,
1
2
(ρ − ηs˜(ρ)), 1
2
(ηs˜(ρ)+1 − ρ)
}
,
and gbs = min
{
pis,
1
2
(ρ − ηs˜(ρ)−1), 1
2
(ηs˜(ρ)+1 − ρ)
}
.
D.3 Regret Bound of R(T, B)
Form Lemma 5, we can see that the boundary case has a worse bound O(√T logT) than the non-boundary case
O(logT). Hence, with (14) and Lemma 5, we have the worst-case regret bound of C3T-Budget-E in the theorem
with
M =
∑
s∈S
∑
k:ps,k (a∗s )≤ζ
c
∆
(s)
s,k
+
s˜(ρ)−1∑
s=1
∑
k∈K
27
2gb
s˜(ρ)
[
∆
(s)
s˜(ρ),k
]2 + S∑
s=s˜+1
∑
k∈K
27
2gbs
[
∆
(s˜)
s,k
]2 + 2S(K + ∆¯),
and gbs = min
{
pis,
1
2
(ρ − ηs˜(ρ)−1), 1
2
(ηs˜(ρ)+1 − ρ)
}
.

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E DESCRIPTION OF C3T-Budget-E
For C3T-Budget-E, we consider the following formulation:
maximize EΠ(T, B)
subject to P
[
SΠ,s(T, B) ≤ ζ
] ≥ 1 − δs, ∀s ∈ S∑T
t=1 Zt ≤ B.
where we have simply substituted the objective function DΠ(T, B) in the limited-budget C3T problem (See (2)
in our main paper) with EΠ(T, B). With this formulation, the agent tries to achieve high efficacies (rather than
low dose recommendation error), which results in focusing on subgroups with high efficacies. We now provide a
detailed description of C3T-Budget-E to solve the above problem.
Algorithm 2 C3T-Budget-E
1: Input: Time-horizon T , budget B, and subgroup arrival distributions pis’s
2: Initialize: τ = T , b = B, t = 1
3: while t ≤ T do
4: aˆs(t) ←
∑K
k=1 aˆs,k (t−1)Ns,k (t−1)
Ns (t−1) , ∀s ∈ S
5: Ks(t) = {k ∈ K : ps,k(aˆs(t) + αs(t)) ≤ ζ }, ∀s ∈ S
6: if b > 0 then
7: if NH(t)(t) ≤ K then
8: Sample each dose once I(t) = NH(t)(t)
9: else
10: k∗s(t) ← argmaxk∈Ks qˆs,k(t), ∀s ∈ S
11: qˆ∗s(t) ← maxk∈Ks qˆs,k(t), ∀s ∈ S
12: Obtain ψˆ (b/τ)’s by solving the LP problem (See (3) in our main paper) with ordered qˆ∗s(t)’s
13: Allocate dose I(t)=
{
k∗
H(t)(t), with probability ψˆH(t)(b/τ),
0, otherwise.
14: end if
15: end if
16: Observe the efficacy Xt and toxicity Yt
17: Update τ, b, Ns(t), Ns,k(t), q¯s,k(t), p¯s,k(t)
18: aˆs,k(t) ← argmina |ps,I (t)(a) − p¯s,I (t)(t)|, ∀s ∈ S, ∀k ∈ K
19: t ← t + 1
20: end while
F DESCRIPTION OF BASELINE ALGORITHMS
To evaluate the performance of C3T-Budget and C3T-Budget-R, we implement the following baseline algorithms:
• Contextual UCB (C-UCB) (Auer et al., 2002; Varatharajah et al., 2018): C-UCB is an extended version
of a traditional UCB algorithm in Auer et al. (2002) for a contextual bandits. We implement it by running S
instances of the tradition UCB algorithm for each subgroup as introduced in Zhou (2015). In the algorithm,
the safety and budget constraints are not considered. The algorithm updates the empirical expected efficacy
of each dose for each subgroup and its confidence bound. It also updates the empirical toxicities, but they are
used only for the recommendation. In each round, the algorithm chooses the dose having the highest UCB
index for the subgroup arrived in the round. At the end of trial, it recommends a dose for each subgroup as:
d¯s = argmaxk:pˆs,k ≤ζ,q¯s,k (t)≥θ q¯s,k , where pˆs,k and qˆs,k are the empirical expected toxicity and efficacy of dose
k for subgroup s.
• Contextual KL-UCB (C-KL-UCB) (Garivier and Cappe´, 2011; Varatharajah et al., 2018): C-KL-UCB
is an extended version of a KL-UCB algorithm in Garivier and Cappe´ (2011) for a contextual bandits. Similar
to C-UCB, we implement it by using S instances of KL-UCB. The algorithm is same with C-UCB except for
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using the KL-UCB index instead of the UCB index, which is given by
qˆs,k(t) = sup{q ≥ q¯s,k(t) : Ns,k(t − 1)I(q¯s,k), q) ≤ log Ns(t) + log log Ns(t)},
where I(p, q) = p log pq + (1 − p) log 1−p1−q is the Kullback-Leibler divergence.
• Contextual independent Thompson sampling (C-Indep-TS) (Aziz et al., 2019): C-Indep-TS is an
extended version of an Indep-TS algorithm in Aziz et al. (2019); Thompson (1933) for a contextual bandits.
Similar to other extended algorithms, we implement it by using S instances of Indep-TS. In Indep-TS, a
Bayesian approach is used to estimate the efficacy and toxicity as follows:
qˆs,k(t) ∼ Beta(αqs,k(t), βqs,k(t)) and pˆs,k(t) ∼ Beta(αps,k(t), βps,k(t)),
where α
q
s,k
(t) = Xs,k(t) + 1, βqs,k(t) = Ns,k(t) − Xs,k(t) + 1, Xs,k(t) =
∑t
τ=1 I{H(τ) = s, I(τ) = k}X(τ), αps,k(t) =
Ys,k(t) + 1, βps,k(t) = Ns,k(t) − Ys,k(t) + 1, and Ys,k(t) =
∑t
τ=1 I{H(τ) = s, I(τ) = k}Y (τ). In each round t, the
efficacy and toxicity for subgroup H(t) is realized based on the posterior distribution as above equation,
and then, the dose k that has the maximum realized efficacy qˆH(t),k is chosen. At the end of the trial, it
recommends a dose for each subgroup as: d¯s = argmaxk:pˆs,k (t)≤ζ,qˆs,k (t)≥θ qˆs,k(t).
• Contextual 3+3 (C-3+3) (Storer, 1989): C-3+3 is an extended version of a 3+3 clinical trial design in
Storer (1989) for a contextual model. Similar to other extended algorithms, we implement it by using S
instances of 3+3 design. In 3+3 design, for each subgroup, the lowest dose is treated to 3 patients. Then,
it observes the toxicity of the patients. If the agent observes the toxicity from none of patients, then the
next dose is treated to another 3 patients. If the agent observes only one toxicity, the same dose is treated
to additional 3 patients. If the agent still observes only one toxicity among the 6 patients, then the next
dose is treated to another 3 patients. Otherwise, the trial is stopped and the dose treated before stopping
is recommended. If the instance of 3+3 design for a subgroup is stopped once, then the patients in the
subgroup are skipped.
